PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 20260 citationsOpen Access

Agonists and antagonists show different unbinding paths from the TLR8 receptor

VTValerij TalagayevGWGerhard WolberANAriane Nunes-Alves

Key Points

  • The aim is to explore how different TLR8 ligands unbind from the receptor to inform drug design.
  • Utilized τ-random acceleration molecular dynamics (τRAMD) simulations.
  • Characterized the unbinding paths of one TLR8 agonist and five TLR8 antagonists.
  • Analyzed data to identify internal and external unbinding pathways.
  • Discovered two unbinding pathways: internal toward TIR domain and external away from TIR domain.
  • The TLR8 agonist exclusively used the external pathway for unbinding.
  • Cationic antagonists only exited through the internal pathway, while neutral antagonists used both.

Abstract

Toll-like receptors (TLRs) form the first barrier of the innate immune system. TLR8 is an important target to treat autoimmune diseases since its ligand-induced degree of activation regulates immune response and associated hyperinflammation. Molecular dynamics (MD) simulations have been used to investigate interactions of TLRs with ligands, but the mechanism of ligand unbinding remains elusive. We therefore applied τ-random acceleration molecular dynamics (τRAMD) simulations to characterize the unbinding paths of one TLR8 agonist and five TLR8 antagonists. Data analysis of the simulations led to the discovery of two possible unbinding pathways: the internal pathway, directed toward the Toll-interleukin-1 receptor (TIR) domain, and the external pathway, pointing away from the TIR domain. Remarkably, some ligands showed clear path preferences: the TLR8 agonist exited through the external unbinding pathway only, while the cationic antagonists exited through the internal pathway only. The neutral antagonists used both pathways. The mechanistic insights obtained can assist in the design of improved TLR modulators.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Talagayev et al. (2025) studied this question.

synapsesocial.com/papers/69aa70d6531e4c4a9ff5b0c3https://doi.org/10.14279/depositonce-24656
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Structure-Based Design of Potent TLR7/8/9 Triple Antagonists: Overcoming High Tissue Distribution and Reactive Metabolite Liabilities2026
  2. 2Small molecule agonists of Toll-like receptors 7 and 8: an updated patent review 2021 – 20252026
  3. 3Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications2024 · 66 citations
  4. 4Discovery of Novel Small Molecule Dual Inhibitor Targeting Toll-Like Receptors 7 and 92024 · 17 citations
  5. 5Recent advances in the design and development of small molecules targeting the TLR4 signaling pathway2026